Carmelo Milano1, Francis D Pagani2, Mark S Slaughter2, Duc Thinh Pham2, David R Hathaway2, Mary V Jacoski2, Kevin B Najarian2, Keith D Aaronson2. 1. From the Duke University Medical Center, Durham, NC (C.M.); University of Michigan Medical Center, Ann Arbor (F.D.P., K.D.A.); University of Louisville, KY (M.S.S.); Tufts University School of Medicine, Boston, MA (D.T.P.); and HeartWare, Inc, Framingham, MA (D.R.H., M.V.J., K.B.N.). milan002@mc.duke.edu. 2. From the Duke University Medical Center, Durham, NC (C.M.); University of Michigan Medical Center, Ann Arbor (F.D.P., K.D.A.); University of Louisville, KY (M.S.S.); Tufts University School of Medicine, Boston, MA (D.T.P.); and HeartWare, Inc, Framingham, MA (D.R.H., M.V.J., K.B.N.).
Abstract
BACKGROUND: Cardiac valve procedures are commonly performed concurrently during implantation of left ventricular assist devices, but the added procedural risk has not been studied in detail. METHODS AND RESULTS: Data from patients receiving the HeartWare Ventricular Assist Device in the ADVANCE bridge to transplant (BTT) trial and continued access protocol were reviewed. Of 382 consecutive patients who completed follow-up between August 2008 and June 2013 (mean time on support 389 days, median 271 days), 262 (68.6%) underwent isolated HeartWare Ventricular Assist Device implantation, 75 (19.6%) a concurrent valve procedure, and 45 (11.8%) concurrent nonvalvular procedures. Of the concurrent valve procedures, 56 were tricuspid, 13 aortic, and 6 mitral. Survival was similar between groups (79% for concurrent valve procedures and 85% for HeartWare Ventricular Assist Device only at 1 year; P=0.33). Concurrent valve procedures were also associated with increased unadjusted early right heart failure (RHF). A multivariable analysis for death and RHF (121 total events) identified female sex (odds ratio=2.0 [95% confidence interval, 1.2-3.3; P=0.0053]) and preimplant tricuspid regurgitation severity (odds ratio=2.9 [95% confidence interval, 1.8-4.8, P<0.0001]) as independent predictors while concurrent tricuspid valve procedures (TVP) were not predictors. Furthermore, patients with significant preimplant tricuspid regurgitation who did not receive a TVP experienced an increased rate of late RHF compared with those who received TVP (0.19 versus 0.05 events per patient-year, respectively; P=0.024). CONCLUSIONS: Compared with HeartWare Ventricular Assist Device alone, survival was equivalent for the concurrent valve procedure group. Tricuspid regurgitation severity was the most important predictor of increased postoperative RHF, and concurrent TVP was not an independent predictor of RHF overall. Concurrent TVP may reduce the rate of late RHF for patients with significant preimplant tricuspid insufficiency. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00751972.
BACKGROUND: Cardiac valve procedures are commonly performed concurrently during implantation of left ventricular assist devices, but the added procedural risk has not been studied in detail. METHODS AND RESULTS: Data from patients receiving the HeartWare Ventricular Assist Device in the ADVANCE bridge to transplant (BTT) trial and continued access protocol were reviewed. Of 382 consecutive patients who completed follow-up between August 2008 and June 2013 (mean time on support 389 days, median 271 days), 262 (68.6%) underwent isolated HeartWare Ventricular Assist Device implantation, 75 (19.6%) a concurrent valve procedure, and 45 (11.8%) concurrent nonvalvular procedures. Of the concurrent valve procedures, 56 were tricuspid, 13 aortic, and 6 mitral. Survival was similar between groups (79% for concurrent valve procedures and 85% for HeartWare Ventricular Assist Device only at 1 year; P=0.33). Concurrent valve procedures were also associated with increased unadjusted early right heart failure (RHF). A multivariable analysis for death and RHF (121 total events) identified female sex (odds ratio=2.0 [95% confidence interval, 1.2-3.3; P=0.0053]) and preimplant tricuspid regurgitation severity (odds ratio=2.9 [95% confidence interval, 1.8-4.8, P<0.0001]) as independent predictors while concurrent tricuspid valve procedures (TVP) were not predictors. Furthermore, patients with significant preimplant tricuspid regurgitation who did not receive a TVP experienced an increased rate of late RHF compared with those who received TVP (0.19 versus 0.05 events per patient-year, respectively; P=0.024). CONCLUSIONS: Compared with HeartWare Ventricular Assist Device alone, survival was equivalent for the concurrent valve procedure group. Tricuspid regurgitation severity was the most important predictor of increased postoperative RHF, and concurrent TVP was not an independent predictor of RHF overall. Concurrent TVP may reduce the rate of late RHF for patients with significant preimplant tricuspid insufficiency. CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT00751972.
Authors: Supriya Shore; Michael J Pienta; Tessa M F Watt; Gardner Yost; Whitney A Townsend; Lourdes Cabrera; Michael D Fetters; Carol Chenoweth; Keith D Aaronson; Francis D Pagani; Donald S Likosky Journal: J Heart Lung Transplant Date: 2021-10-22 Impact factor: 13.569
Authors: Yaron D Barac; Alina Nicoara; Muath Bishawi; Jacob N Schroder; Mani A Daneshmand; Nazish K Hashmi; Eric Velazquez; Joseph G Rogers; Chetan B Patel; Carmelo A Milano Journal: JACC Heart Fail Date: 2019-12-11 Impact factor: 12.035
Authors: Michael S Kiernan; E Wilson Grandin; Marshall Brinkley; Navin K Kapur; Duc Thinh Pham; Robin Ruthazer; J Eduardo Rame; Pavan Atluri; Edo Y Birati; Guilherme H Oliveira; Francis D Pagani; James K Kirklin; David Naftel; Robert L Kormos; Jeffrey J Teuteberg; David DeNofrio Journal: Circ Heart Fail Date: 2017-10 Impact factor: 8.790
Authors: Claudio J R Gomez Hamacher; Carolin Torregroza; Najla Sadat; Daniel Scheiber; Jil-Cathrin von der Beek; Ralf Westenfeld; Ivonne Jeanette Knorr; Martin Sager; Artur Lichtenberg; Diyar Saeed Journal: JTCVS Open Date: 2020-09-24